HEALIUS LIMITED (HLS)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:

HLS - HEALIUS LIMITED
FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 2.39
Index: ASX200 | ASX300 | ALL-ORDS
Healius, formerly Primary Health Care, is an Australian provider of Pathology, Diagnostic and Day Hospital services. It has been listed since 1998.
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$3.03
23 Mar |
OPEN $3.00 |
HIGH $3.07 |
3,946,579 LOW $3.00 |
TARGET | |||||
|
|||||
Franking for last dividend paid out: 100% |
OTHER COMPANIES IN THE SAME SECTOR | |||
EBO . SLA . CAJ . GXL . HSO . MPL . MVF . NHF . RHC . SHL . VRT . MDR . M7T . HLA . PSQ . SIL . PKS . ONT . DOC . BMT . NVL . AHX . ALC . ACL . |
FNARENA'S MARKET CONSENSUS FORECASTS
Title | FY21 Actual |
FY22 Actual |
FY23 Forecast |
FY24 Forecast |
---|---|---|---|---|
EPS (cps) | xxx | 49.9 | 5.8 | xxx |
DPS (cps) | xxx | 16.0 | 1.7 | xxx |
EPS Growth | xxx | 100.0% | - 88.3% | xxx |
DPS Growth | xxx | 20.8% | - 89.2% | xxx |
PE Ratio | xxx | N/A | 50.0 | xxx |
Dividend Yield | xxx | N/A | 0.6% | xxx |
Div Pay Ratio(%) | xxx | 32.0% | 29.6% | xxx |
Last ex-div: 07/09 - ex-div 6c (franking 100%)
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | 49.9 |
DPS All | xxx | xxx | xxx | xxx | xxx | 16.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 2,336.2 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 337.6 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | 573.8 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | 12.58 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | 15.56 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | 8.98 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | 7.43 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | 15.56 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | 13.37 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | 394.3 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 224 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | 1,555 M |
Total Debt | xxx | xxx | xxx | xxx | xxx | 1,779 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | 2,344 M |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 81 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | 1.09 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 93.5 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 4.00 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 1,547 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 322 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | - |
Investments - Total | xxx | xxx | xxx | xxx | xxx | 6 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development

Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
HLS STOCK CHART

FNArena News on HLS
1 |
Australian Broker Call *Extra* Edition – Mar 24, 202312:31 PM - Daily Market Reports |
2 |
Rudi’s Comprehensive February 2023 ReviewMar 23 2023 - Feature Stories |
3 |
Rudi’s View: All-Weather Stocks – Back In FashionMar 22 2023 - Rudi's View |
4 |
No Enthusiasm To Combine ACL & HealiusMar 21 2023 - Australia |
5 |
Rudi’s View: Fear & Greed (Rinse & Repeat)Mar 15 2023 - Rudi's View |
Latest Healthcare services News
1 |
No Enthusiasm To Combine ACL & HealiusMar 21 2023 - Australia |
2 |
Dr Boreham’s Crucible: AlcidionDec 13 2022 - Small Caps |
3 |
No Straight Covid-Relief For Ramsay Health CareNov 15 2022 - Australia |
4 |
Dr Boreham’s Crucible: Mach7 TechnologiesNov 14 2022 - Small Caps |
5 |
Negative Industry Trends Impact Australian Clinical LabsAug 12 2022 - Small Caps |
6 |
Healius Offers Digital Carrot, Base Remains SoftMay 25 2022 - Australia |
7 |
Ramsay Stakes Future on Mental HealthDec 20 2021 - Australia |
8 |
Ramsay Health Care: Finally A Break-OutNov 09 2021 - Technicals |
9 |
Funding Overhang Weighs On Ramsay’s ReboundJun 10 2021 - Australia |
10 |
Treasure Chest: More Pfizer Growth For Ebos GroupMay 24 2021 - Treasure Chest |